Anti-IgE Antibodies

Ralph Adams (Inventor), Thomas Allen Ceska (Inventor), Anna Marie Davies (Inventor), Alistair James Henry (Inventor), Xiaofeng Liu (Inventor), James Michael McDonnell (Inventor), Brian John Sutton (Inventor), Marta Katarzyna Westwood (Inventor)

Research output: Patent


The present invention relates to the area of improved anti-IgE antibodies and antigen binding agents, and compositions thereof, which target IgE, for instance: for use in treating disorders caused by IgE (such as allergic responses, or certain autoimmune responses); and, in particular, disorders caused by the interaction of IgE with the FcεRI receptor. In particular, this invention relates to improved anti-IgE antibodies and antigen binding agents related to novel mutants of omalizumab (Xolair®). The improved anti-IgE antibodies and antigen binding agents of the invention may have improved affinity for IgE and/or an improved interaction with the Cε2 domain of IgE and/or an improved modified epitope on IgE (for instance further involving the Cε2 domain of IgE) and/or the ability to disassociate IgE from the FcεRI receptor for instance at pharmaceutically-relevant concentrations. In one aspect, improved or novel treatments for IgE mediated disorders are disclosed in which IgE is targeted (for instance free IgE and/or IgE complexed with the FcεRI receptor).
Original languageEnglish
Patent numberWO 2017/211928 A1
Priority date10/06/2016
Filing date8/06/2017
Publication statusPublished - 14 Dec 2017


Dive into the research topics of 'Anti-IgE Antibodies'. Together they form a unique fingerprint.

Cite this